Hospital Admissions of Patients with Osteogenesis Imperfecta in the English NHS

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2021 Jan 7

PMID 33411004

Citations 9

Authors

S Kolovos

M K Javaid

R Pinedo-Villanueva

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to characterise hospital use by patients with osteogenesis imperfecta (OI) in the English National Health Service (NHS).

Methods: Routinely collected aggregate data about all inpatient hospital records from patients with OI were used for the period 1 April 2014 to 31 March 2018. Information was extracted on number of admissions, number of patients, length of stay, and costs. Hospital use was summarised using descriptive statistics, categorising patients into 5-year age groups.

Results: There were 16,245 hospital admissions for OI patients during the analysis period, with a total cost to the NHS of £24,052,451. Of the 4370 patients involved, 2700 (62%) were female. Female patients averaged 3.3 admissions per year and male patients 4.4 admissions per year. Patients aged 0 to 14 years old accounted for 54% of all admissions. Those aged 90 to 94 years had the longest average length of stay per admission (10.5 days) of any age group. Elective admissions cost on average £1260 and non-elective admissions £2529. Over the 4-year study period, number of admissions increased on average by 2.1% per year and number of patients by 6.4% per year.

Conclusion: The treatment of patients with OI is associated with a significant number of hospital admissions at an important cost for the NHS, with both number of admissions and costs increasing over time. Children below the age of 14 years had more admissions at a greater total cost than other ages, while the oldest adults had longer average stays and higher costs per admission.

Citing Articles

An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta....

Sagar R, Astrom E, Chitty L, Crowe B, David A, DeVile C BMJ Open. 2024; 14(6):e079767.

PMID: 38834319 PMC: 11163617. DOI: 10.1136/bmjopen-2023-079767.

The IMPACT Survey: the economic impact of osteogenesis imperfecta in adults.

Hart T, Westerheim I, van Welzenis T, Semler O, Raggio C, Rauch F Orphanet J Rare Dis. 2024; 19(1):222.

PMID: 38831282 PMC: 11149192. DOI: 10.1186/s13023-024-03218-6.

Demographics and medical burden of osteogenesis imperfecta: a nationwide database analysis.

Shih C, Li C, Chang Y, Hwang J, Tsai M, Chou Y Osteoporos Int. 2024; 35(7):1185-1193.

PMID: 38563961 DOI: 10.1007/s00198-024-07051-2.

The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers.

Westerheim I, Hart T, van Welzenis T, Wekre L, Semler O, Raggio C Orphanet J Rare Dis. 2024; 19(1):128.

PMID: 38515144 PMC: 10956293. DOI: 10.1186/s13023-024-03126-9.

The burden of hospital admissions for skeletal dysplasias in Sri Lanka: a population-based study.

Kolambage Y, Walpita Y, Liyanage U, Dayaratne B, Dissanayake V Orphanet J Rare Dis. 2023; 18(1):279.

PMID: 37684696 PMC: 10485930. DOI: 10.1186/s13023-023-02884-2.

References

van Dijk F, Sillence D . Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014; 164A(6):1470-81. PMC: 4314691. DOI: 10.1002/ajmg.a.36545. View

Song Y, Zhao D, Li L, Lv F, Wang O, Jiang Y . Health-related quality of life in children with osteogenesis imperfecta: a large-sample study. Osteoporos Int. 2018; 30(2):461-468. DOI: 10.1007/s00198-018-4801-5. View

Vanz A, Van de Sande Lee J, Pinheiro B, Zambrano M, Brizola E, da Rocha N . Health-related quality of life of children and adolescents with osteogenesis imperfecta: a cross-sectional study using PedsQL™. BMC Pediatr. 2018; 18(1):95. PMC: 5833128. DOI: 10.1186/s12887-018-1077-z. View

Hald J, Folkestad L, Harslof T, Brixen K, Langdahl B . Health-Related Quality of Life in Adults with Osteogenesis Imperfecta. Calcif Tissue Int. 2017; 101(5):473-478. DOI: 10.1007/s00223-017-0301-4. View

Matsushita M, Mishima K, Yamashita S, Haga N, Fujiwara S, Ozono K . Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta. J Bone Miner Metab. 2019; 38(1):109-116. DOI: 10.1007/s00774-019-01033-9. View

Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J . Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis. 2016; 11(1):160. PMC: 5126812. DOI: 10.1186/s13023-016-0538-4. View

Forlino A, Cabral W, Barnes A, Marini J . New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7(9):540-57. PMC: 3443407. DOI: 10.1038/nrendo.2011.81. View

Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P . Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 2017; 46(4):1093-1093i. PMC: 5837677. DOI: 10.1093/ije/dyx015. View

Tosi L, Oetgen M, Floor M, Huber M, Kennelly A, McCarter R . Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis. 2015; 10:146. PMC: 4650321. DOI: 10.1186/s13023-015-0362-2. View

10.

Land C, Rauch F, Travers R, Glorieux F . Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2006; 40(3):638-44. DOI: 10.1016/j.bone.2006.10.010. View

11.

Glorieux F, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339(14):947-52. DOI: 10.1056/NEJM199810013391402. View

12.

Folkestad L, Hald J, Ersboll A, Gram J, Hermann A, Langdahl B . Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. J Bone Miner Res. 2016; 32(1):125-134. DOI: 10.1002/jbmr.2920. View

13.

Hald J, Evangelou E, Langdahl B, Ralston S . Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2014; 30(5):929-33. DOI: 10.1002/jbmr.2410. View

14.

Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G . Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010; 6:367-81. PMC: 2940745. DOI: 10.2147/tcrm.s5932. View

15.

Shapiro J, Lietman C, Grover M, Lu J, Nagamani S, Dawson B . Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res. 2013; 28(7):1523-30. PMC: 3688672. DOI: 10.1002/jbmr.1891. View

16.

Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund A . Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J Med Genet. 2012; 50(1):21-4. DOI: 10.1136/jmedgenet-2012-101307. View

17.

Kolovos S, Nador G, Kishore B, Streetly M, Rabin N, Chantry A . Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. J Bone Oncol. 2019; 17:100243. PMC: 6579752. DOI: 10.1016/j.jbo.2019.100243. View